Quality of life

Gagnon, Louise
March 2009
Dermatology Times;Mar2009, Vol. 30 Issue 3, p49
Trade Publication
The article discusses the use of combination therapy in treating psoriasis. It explains the use of methotrexate systemic retinoids or phototherapy as part of a combined therapy with biologic agents for treating psoriasis. According to Doctor Alan Menter, chairman of the psoriasis research unit at the Baylor University Medical Center in Dallas, Texas, combination therapy is frequently utilized to ensure that patients maintain adequate control of psoriasis.


Related Articles

  • PHASE 3 TRIAL INDICATES ADALIMUMAB EFFICACY, SAFETY. Guttman, Cheryl // Dermatology Times;May2007 Psoriasis Supplement, Vol. 28, ps10 

    The article focuses on the results of the North American phase three clinical trial regarding the efficacy of adalimumab for the treatment of moderate-to-severe chronic plaque psoriasis. According to doctor and researcher Alan Menter, the data confirm the safety and effectiveness of the drug....

  • Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18 

    The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral...

  • Gene therapy: A still unexplored psoriasis frontier. Carlton, Toni // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS19 

    Reports that researchers are still searching for ideal delivery systems for the treatment of psoriasis, according to Alan Menter. Significance of gene therapy in treating complex skin diseases; Problems posed by delivery systems; Characteristics of an ideal delivery systems. INSET: AAD begins...

  • Fusion protein denileukin diftitox clears psoriasis. Kuznar, Wayne // Dermatology Times;Oct2001, Vol. 22 Issue 10, p18 

    Reports the effectiveness of dermatologic agents denileukin diftitox in clearing skin lesions in patients with psoriasis vulgaris in New York. Antipsoriatic activity of denileukin; Daily dosage administration; Decrease of lesional T-cells in the dermis.

  • Chapter 6: Phototherapy and photochemotherapy. Menter, Alan; Smith, Catherine; Barker, Jonathan // Fast Facts: Psoriasis (Health Press);2008, p59 

    Chapter 6 of the book "Fast Facts: Psoriasis" Third edition is presented. This chapter focuses on the use of phototherapy and photochemotherapy (PUVA) in psoriasis treatment. Phototherapy is viewed by patients as an escape from the problems of topical agents in general. The application of...

  • Various pharmacological options are used to treat nail psoriasis, but choosing the best regimen is difficult.  // Drugs & Therapy Perspectives;Jun2010, Vol. 26 Issue 6, p8 

    Nail involvement in psoriasis is common and can be distressing. It can be treated with a range of treatment options, including topical medications, intralesional corticosteroids, phototherapy, radiation therapy, systemic therapies and biological agents. However, evidence for their efficacy in...

  • Etanercept.  // Reactions Weekly;12/4/2010, Issue 1330, p19 

    The article describes the case of a 64-year-old man with a 35-year history of chronic plaque psoriasis who developed disseminated superficial porokeratosis (DSP) following etanercept therapy for extensive psoriasis.

  • Managing psoriasis in children and young people. Van Onselen, Julie // Nurse Prescribing;Jul2013, Vol. 11 Issue 7, p330 

    Psoriasis is an inflammatory condition which manifests in the skin and joints. Psoriasis can affect children and young people; the late teens and early twenties are a peak time for psoriasis developing for the first time. Psoriasis can affect quality of life in children and young people. Nurses...

  • Amevive Has Excellent Dose Response/Side-Effect Profile.  // Biotech Business;Jul99, Vol. 12 Issue 7, p1 

    Reports the result of the controlled trial of AMEVIVE, a recombinantly Engineered LFA-3/IgG1 Human Fusion Protein of Biogen Inc., in patients with moderate-to-severe chronic plaque psoriasis. Measurement of disease severity by Physician Global Assessment and the Psoriasis Activity and Severity...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics